Assembly Biosciences (NASDAQ:ASMB) Earns “Buy” Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $50.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 80.51% from the stock’s previous close. HC Wainwright also issued estimates for Assembly Biosciences’ Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.10) EPS, Q4 2027 earnings at $1.67 EPS and FY2030 earnings at $3.23 EPS.

A number of other analysts also recently issued reports on the company. Wall Street Zen raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $41.75.

Assembly Biosciences Stock Down 4.1%

Shares of ASMB opened at $27.70 on Thursday. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $39.71. The stock has a fifty day simple moving average of $27.93 and a two-hundred day simple moving average of $29.74. The company has a market capitalization of $439.32 million, a PE ratio of -37.43 and a beta of 1.11.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The firm had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $7.42 million. As a group, equities analysts anticipate that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its position in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 3,319 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $147,000. Acadian Asset Management LLC grew its stake in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at approximately $228,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $251,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.